Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Teijin ( (JP:3401) ) has provided an announcement.
Teijin Limited announced significant financial adjustments in its fourth-quarter results for the fiscal year ended March 2025, primarily due to impairment losses and extraordinary income and loss. The company recorded an impairment loss of 28 billion yen related to its diabetes treatments in Japan, which underperformed due to competitive pressures and anticipated drug price revisions. Additionally, Teijin resolved to transfer shares of its affiliate, Teijin Automotive Technologies NA Holdings, resulting in a loss on valuation of shares and provisions for doubtful accounts and guarantees. Despite these adjustments, the company’s annual financial forecast remains unchanged, with no impact on consolidated profit/loss for the fiscal year.
More about Teijin
Teijin Limited operates in the pharmaceutical and materials industries, focusing on the development and sale of medical treatments and advanced materials. The company is known for its innovative solutions in healthcare and high-performance materials, catering to a global market.
YTD Price Performance: -8.33%
Average Trading Volume: 700,305
Technical Sentiment Signal: Sell
Current Market Cap: Yen231.4B
For a thorough assessment of 3401 stock, go to TipRanks’ Stock Analysis page.